aTyr Pharma Inc (NASDAQ:LIFE) shares saw an uptick in trading volume on Thursday . 1,308,183 shares were traded during trading, an increase of 192% from the previous session’s volume of 447,423 shares.The stock last traded at $0.68 and had previously closed at $0.64.

Several brokerages have recently weighed in on LIFE. Piper Jaffray Companies dropped their price objective on shares of aTyr Pharma from $3.00 to $1.80 and set an “overweight” rating on the stock in a report on Monday, October 8th. Citigroup upgraded shares of aTyr Pharma from a “sell” rating to a “neutral” rating and dropped their price objective for the company from $1.00 to $0.75 in a report on Thursday, August 16th. BMO Capital Markets dropped their price objective on shares of aTyr Pharma from $2.00 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, August 15th. Finally, Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $1.64.

The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $19.07 million, a price-to-earnings ratio of -0.34 and a beta of 2.88.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). On average, equities research analysts forecast that aTyr Pharma Inc will post -1.29 earnings per share for the current year.

In other aTyr Pharma news, Director Paul Schimmel bought 164,411 shares of the stock in a transaction that occurred on Thursday, August 30th. The shares were bought at an average price of $0.74 per share, for a total transaction of $121,664.14. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Jill Marie Broadfoot bought 64,000 shares of the stock in a transaction that occurred on Thursday, September 20th. The stock was acquired at an average price of $0.83 per share, for a total transaction of $53,120.00. The disclosure for this purchase can be found here. Insiders purchased a total of 297,160 shares of company stock worth $225,398 in the last 90 days. 25.00% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in aTyr Pharma stock. Dimensional Fund Advisors LP boosted its position in aTyr Pharma Inc (NASDAQ:LIFE) by 33.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 114,449 shares of the biotechnology company’s stock after purchasing an additional 28,699 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of aTyr Pharma worth $303,000 as of its most recent SEC filing. Institutional investors own 44.54% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “aTyr Pharma (LIFE) Sees Strong Trading Volume” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/11/10/atyr-pharma-life-sees-strong-trading-volume-2.html.

aTyr Pharma Company Profile (NASDAQ:LIFE)

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Read More: Preferred Stock

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.